‘Why OpsisDx?’ is a blog series written by people part of the Entopsis-verse and offers insights into potential OpsisDxTM addressable medical conditions.

Irritable bowel syndrome (IBS) is one of the most commonly encountered conditions in primary care and gastroenterology clinics. This condition has a prevalence of around 10-15% worldwide and, while this condition is not lethal, patients experience a sharp decline in their quality of life because of how debilitating this condition can be (2). Hallmark symptoms of IBS include changes in bowel habits, abdominal bloating and chronic abdominal discomfort/pain. (1). The etiology of this condition is not fully understood

1) CLIA Lab Director (Ph.D. with LDT development experience)
Location: Orlando, FL, USA

2) CLIA Medical Technologist (management experience needed)
Location: Orlando, FL, USA

3) Computer Scientist – Machine Learning
Location: Singapore, Singapore

4) Online Sales / Marketing
Location: global (all work is online)

5) Personal / Business Assistant to CEO (…a jack of all trades)
Location: Miami, FL, USA

6) Content Writer (little work experience necessary, but must be a daring writer)
Location: Miami, FL, USA

info@entopsis.com

Our team of multi-disciplinary scientists and engineers have once again improved on the NuTec Slide. This was only made possible by building on past insights and proprietary know-how. The latest version of NuTec Slides show improved reproducibility and sample discernment, while being able to handle a wider range of sample intensities. The Gen 5 NuTec Slide will be used for commercial applications in the U.S.

‘Why OpsisDx?’ is a blog series written by people part of the Entopsis-verse and offers insights into potential OpsisDxTM addressable medical conditions.

Cancer is probably one of the most apprehended conditions in the modern world. Raising to the spotlight in the 20th century and becoming increasingly prevalent while also acquiring higher incidence rates, it is no surprise why this condition has spiked scientists’ interest as well as fueled funding on diagnostics and therapeutics (1). As of 2018, there were 18mil new cases of cancer worldwide, and, around 430K deaths caused by cancer in the pancreas alone (2). 

As illustrated by

Our team submitted a research manuscript for peer-review describing the unique approach utilized by OpsisDx to categorize samples and patients. We included data from a clinical study as a means of validating the platform for clinical use.

A shortage of COVID-19 testing supplies is hampering people’s ability to perform timely RT-PCR testing. A key bottleneck is viral RNA extraction, which involves multiple steps, reagents and devices.

Our team is now investigating whether we can apply our PCRopsis technology and know-how to facilitate direct RT-PCR from nasal-pharyngeal and saliva samples by skipping the RNA extraction step.

Stay tuned for research updates on this promising approach in the battle against the pandemic.

Check-out our other PCRopsis products that allow you to perform PCR directly from clinical samples: PCRopsis.com

Entopsis recently signed licensing agreements with a CLIA-certified diagnostic laboratory to commercialize 4 oncology OpsisDx tests in the USA. This represents the first step in bringing OpsisDx to market.

The Entopsis team continues to prove-out the capabilities of OpsisDx for the early detection of other cancers, infectious diseases and mental illnesses. These efforts are aimed at establishing additional partnerships globally for a variety of medical conditions so that we can offer better health outcomes to all people.

Preliminary results are in from the on-going international clinical study exploring the ability of OpsisDx to accurately identify people with multiple diseases.

Highlights:

  1. OpsisDx distinguishes between people with cancer, hepatitis B viral and healthy controls
  2. OpsisDx accurately identifies patient’s cancer tissue of origin (lung, prostate, breast, liver or colorectal)
  3. Hepatitis B viral infection, often linked to increased likelihood for liver cancer, is observed as a distinct category from liver cancer patients
  4. OpsisDx detects more stage I cancers than liquid biopsies as performed by GRAIL

Can OpsisDx distinguish between similar molecules? Let’s say between different salts or isomers of carrageenan or phenol vs cresol?

YES … we observe distinct NuTec profiles for each molecule or mixture, even for molecules with similar structures.

This provides a framework for people to better grasp the inner workings of OpsisDx.